Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9599 posts found.

Roche targets new central nervous system drugs

January 5, 2007 Research and Development

Swiss-based Roche has forged a partnership that could lead to the development of new treatments for schizophrenia, cognitive disorders, Parkinson's …
News

GSK buys Praecis Pharmaceuticals for $59 million

January 4, 2007 Research and Development, Sales and Marketing

GlaxoSmithKline has bought US-based biotech company, Praecis, to further boost its novel cancer pipeline.Its acquisition of Praecis Pharmaceuticals follows the …
News

Diabetic kidney disease drug hits safety obstacle

January 4, 2007 Research and Development, Sales and Marketing

Swiss-based biotech company Speedel has axed its current phase III trial of SPP301 in diabetic kidney disease because of patient …
News

Pharma failing to address MRSA drugs market

January 2, 2007 Research and Development, Sales and Marketing

News that a new strain of the MRSA bug has reached Europe from the US has left drug developers under …
News

Novartis enters late-stage trials for new hepatitis C drug

December 21, 2006 Research and Development, Sales and Marketing

Novartis, in collaboration with a US biotech company, has initiated phase III trials of a chronic hepatitis C drug that …
News

Protherics raises

December 19, 2006 Research and Development

UK-based biotech company Protherics has raised £38 million, which will be split in a three-pronged move to expand its development …
News

GSK’s mock vaccine gets EU positive opinion

December 19, 2006 Research and Development

GlaxoSmithKline Biological's mock pandemic flu vaccine has received a positive opinion from EU regulators.Daronix is intended to protect against flu …
News

National cancer network underpins prostate vaccine trial

December 11, 2006 Research and Development

The UK's National Cancer Research Network has given its backing to a phase IIb trial of a promising vaccine for …
News

GSK buys antibody firm Domantis for

December 11, 2006 Research and Development

GlaxoSmithKline has bought Cambridge-based antibody firm Domantis for £230 million.Domantis, a leader in developing the next generation of antibody therapies, …
News

TroVax a step nearer to orphan status

December 8, 2006 Research and Development

Oxford BioMedica's leading cancer immunotherapy vaccine has received a positive opinion as an orphan drug for renal cancer from the …
News

Closer scrutiny for high-risk clinical trials

December 8, 2006 Research and Development

Wide-ranging changes will be made to the way clinical trials are conducted in the UK following the final report by …
News

New UK body to fast-track breakthrough research

December 8, 2006 Research and Development

Faster approval of NHS clinical trials and NICE recommendations are almost certain following a fundamental shake-up in the way UK …
News

Novartis readies Prexige for European launch

December 8, 2006 Research and Development, Sales and Marketing

Novartis will launch Prexige in its first European markets outside the UK next year following its EMEA approval for osteoarthritic …
News

Get the best from your R&D team

December 6, 2006 Business Services, Research and Development R&D, recruitment

One of the key drivers of much of the recent merger and acquisition activity within the pharmaceutical industry is the …
Feature

Cholesterol drug failure hits Pfizer

December 4, 2006 Research and Development, Sales and Marketing

Pfizer has suffered a major blow with its decision to cancel late-stage pipeline torcetrapib following safety concerns.Torcetrapib, which raises 'good' …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026